Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.

High-dose vitamin D does not prevent allergic disease in newborns

03 Jun 2019

High-dose vitamin D supplementation does not protect against allergic disease, allergic sensitization or diseases during the first year of life, a recent study reports.

Researchers randomly assigned 975 infants to receive either 10 µg (n=489) or 30 µg (n=486) supplementation starting at 2 weeks of age. Food and aeroallergen immunoglobulin E levels, as well as the manifestation of wheezing and allergic diseases, were assessed at 12 months of age.

Serum samples available for analysis were obtained from 723 infants. Sensitization to food allergens and aeroallergens was detected in 15.8 percent (n=114) and 3.5 percent (n=25), respectively. Sensitization to food was significantly more likely to occur in children born to parents with a history of allergic disease (odds ratio [OR], 1.16, 95 percent CI, 1.02–1.33).

The rates of food allergen (15.9 percent vs 15.6 percent; p=0.910; OR, 0.98, 0.66–1.46) and aeroallergen (3.9 percent vs 3.0 percent; p=0.509; OR, 0.76, 0.34–1.71) were comparable among participants who received the 10-µg and 30-µg vitamin D supplement.

Data on allergic diseases and symptoms were available for 770 children at 12 months. Physician diagnoses of wheat (1.3 percent vs 1.6 percent; p=0.77; OR, 1.18, 0.36–3.89) and food allergy (5.2 percent vs 7.0 percent; p=0.318; OR, 1.35, 0.75–2.46), atopic eczema (18.9 percent vs 14.4 percent; p=0.097; OR, 0.72, 0.49–1.01), or asthma (0.3 percent vs 0 percent; p=0.494) were comparable between the 10-µg and 30-µg vitamin D groups.

The same was true for wheezing (10 µg vs 30 µg: 10.3 percent vs 9.7 percent; p=0.781; OR, 0.94, 0.58–1.50), hospitalization for bronchiolitis or wheezing (3.1 percent vs 2.4 percent; p=0.547; OR, 0.78, 0.35–1.74), persistent coughs (5.3 percent vs 6.9 percent; p=0.371; OR, 1.32, 0.72–2.40), or itchy rash (18.9 percent vs 16.5 percent; p=0.067; OR, 0.70, 0.48–1.03).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.